A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in patients with refractory autoimmune diseases who received inadequate response or relapsed from standard of care (SoC). The trial included dose escalation and dose expansion parts.

开始日期2024-12-01

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

NCT06577532

/ Recruiting早期临床1期IIT

A Clinical Study to Investigate Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of mRNA Nanoparticles Encoding KRAS Neoantigens (ABO2102) in Participants With KRAS-mutated Advanced Pancreatic Cancer And Other Solid Tumors

The purpose of this study is to evaluate the safety, immunogenicity, pharmacodynamics, as well as preliminary efficacy of KRAS neoantigen mRNA vaccine (ABO2102) alone and in combination with toripalimab (anti-PD-1 monoclonal antibody) among participants with KRAS-mutated advanced pancreatic cancer and other solid tumors. The trial includes dose escalation (Part I) and dose expansion(Part II) parts.

开始日期2024-09-24

申办/合作机构

上海交通大学医学院附属瑞金医院

[+1]

CTR20232745

/ Recruiting临床1期

一项在系统性标准治疗后进展或转移的晚期实体瘤患者中评估ABO2011单药安全性、药代动力学和药效学（PK/PD）及初步有效性的I期临床研究

试验主要目的是评价ABO2011的安全性和耐受性，并探索最大耐受剂量（MTD）以及确定ABO2011的Ⅱ期临床试验推荐剂量（RP2D）；次要目的是评价ABO2011的初步有效性、PK和PD特征以及免疫原性，同时分析分子标记物与有效性和安全性的关系以及评价外周血中炎性细胞因子、肿瘤组织内部免疫微环境的变化和肿瘤免疫相关基因表达的变化

开始日期2023-09-28

申办/合作机构

苏州艾博生物科技有限公司

[+1]

100 项与苏州艾博生物科技有限公司相关的临床结果

登录后查看更多信息

0 项与苏州艾博生物科技有限公司相关的专利（医药）

登录后查看更多信息

项与苏州艾博生物科技有限公司相关的文献（医药）

2025-03-01·Science Bulletin

Efficacy and safety of an mRNA encoding neutralizing antibody against SARS-CoV-2 in non-human primates

Article

作者: Li, Na ; Huang, Xing-Yao ; Xiong, Xiao-Chuan ; Wang, Lei ; Yue, Can ; Zhao, Suo-Qun ; Chen, Ting ; Yin, Ji-Ye ; Du, Fei-Xue ; Ma, Jian-Rong ; Zhang, Jing-Jing ; Chi, Hang ; Cong, Zhe ; Xue, Jing ; Deng, Yong-Qiang ; Ying, Bo ; Liu, Yun-Peng ; Suo, Xing-Xing ; Zhong, Xia ; Qin, Cheng-Feng ; Wang, Xiangxi

2024-11-01·JOURNAL OF MOLECULAR BIOLOGY

Engineered mRNAs With Stable Structures Minimize Double-stranded RNA Formation and Increase Protein Expression

Article

作者: Gao, Weixiang ; Cao, Ruyin ; Yan, Huanhua ; Liu, Guopeng ; Qin, Qianshan ; Liu, Qi ; Zuo, Wenjie ; Wang, Niangang ; Gao, Peng ; Zhang, Xiaojing ; Yuan, Lei ; Yan, Huayuan

The therapeutic use of synthetic message RNA (mRNA) has been validated in COVID-19 vaccines and shows enormous potential in developing infectious and oncological vaccines. However, double-stranded RNA (dsRNA) byproducts generated during the in vitro transcription (IVT) process can diminish the efficacy of mRNA-based therapeutics and provoke innate immune responses. Existing methods to eliminate dsRNA byproducts are often cumbersome and labor-intensive. In this study, we revealed that a loose mRNA secondary structure and more unpaired U bases in the sequence generally lead to the formation of more dsRNA byproducts during the IVT process. We further developed a predictive model for dsRNA byproducts formation based on sequence characteristics to guide the optimization of mRNA sequences, helping to minimize unwanted immune response and improve the protein expression of mRNA products. Collectively, our study provides novel clues and methodologies for developing effective mRNA therapeutics with minimized dsRNA byproducts and increased protein expression.

2024-06-01·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

NanoMUD: Profiling of pseudouridine and N1-methylpseudouridine using Oxford Nanopore direct RNA sequencing

Article

作者: Gao, Peng ; Hong, Haifeng ; Qin, Qianshan ; Huang, Daiyun ; Liu, Guopeng ; Rong, Rong ; Meng, Jia ; Zhang, Yuxin ; Yan, Huayuan ; Ying, Bo ; Wei, Zhen

Nanopore direct RNA sequencing provided a promising solution for unraveling the landscapes of modifications on single RNA molecules. Here, we proposed NanoMUD, a computational framework for predicting the RNA pseudouridine modification (Ψ) and its methylated analog N1-methylpseudouridine (m1Ψ), which have critical application in mRNA vaccination, at single-base and single-molecule resolution from direct RNA sequencing data. Electric signal features were fed into a bidirectional LSTM neural network to achieve improved accuracy and predictive capabilities. Motif-specific models (NNUNN, N = A, C, U or G) were trained based on features extracted from designed dataset and achieved superior performance on molecule-level modification prediction (Ψ models: min AUC = 0.86, max AUC = 0.99; m1Ψ models: min AUC = 0.87, max AUC = 0.99). We then aggregated read-level predictions for site stoichiometry estimation. Given the observed sequence-dependent bias in model performance, we trained regression models based on the distribution of modification probabilities for sites with known stoichiometry. The distribution-based site stoichiometry estimation method allows unbiased comparison between different contexts. To demonstrate the feasibility of our work, three case studies on both in vitro and in vivo transcribed RNAs were presented. NanoMUD will make a powerful tool to facilitate the research on modified therapeutic IVT RNAs and provides useful insight to the landscape and stoichiometry of pseudouridine and N1-pseudouridine on in vivo transcribed RNA species.

816

项与苏州艾博生物科技有限公司相关的新闻（医药）

2025-05-23

·同写意

科济药业舒瑞基奥仑赛注射液（CT041）的摘要已公布于ASCO网站丨会员动态

ASCO会议细胞疗法临床结果

2025-05-22

·同写意

加科思KRAS G12C抑制剂戈来雷塞获批上市丨会员动态

孤儿药突破性疗法引进/卖出上市批准申请上市

2025-05-22

·同写意

艾里奥斯：值得信赖的制药过滤工艺合作伙伴 | 写意会员

疫苗诊断试剂

100 项与苏州艾博生物科技有限公司相关的药物交易

登录后查看更多信息

100 项与苏州艾博生物科技有限公司相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月03日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床申请批准

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

冻干脂质纳米颗粒（LNP）mRNA新冠疫苗（艾博生物/沃森生物） ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	批准上市
SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine(Suzhou Abogen Biosciences Co., Ltd.) ( SARS-CoV-2 S protein )	新型冠状病毒感染更多	临床2/3期
ABO2011 ( IL-12 )	晚期恶性实体瘤更多	临床1/2期
ABO-1108	带状疱疹更多	临床1期
呼吸道合胞病毒mRNA疫苗（艾博生物）	呼吸道合胞体病毒感染更多	临床1期